Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach

Jodi Maple-Grødem; Anastasia Ushakova; Kenn Freddy Pedersen; Ole-Bjørn Tysnes; Guido Alves; Johannes Lange

doi:10.1016/j.nbd.2023.106281

Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach

Neurobiol Dis. 2023 Oct 1:186:106281. doi: 10.1016/j.nbd.2023.106281. Epub 2023 Sep 4.

Authors

Jodi Maple-Grødem¹, Anastasia Ushakova², Kenn Freddy Pedersen³, Ole-Bjørn Tysnes⁴, Guido Alves⁵, Johannes Lange⁶

Affiliations

¹ Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, Stavanger, Norway; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. Electronic address: jodi.maple@uis.no.
² Section of Biostatistics, Department of Research, Stavanger University Hospital, Stavanger, Norway. Electronic address: anastasia.ushakova@sus.no.
³ Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, Stavanger, Norway; Department of Neurology, Stavanger University Hospital, Stavanger, Norway. Electronic address: kenn.freddy.pedersen@sus.no.
⁴ Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway. Electronic address: ole-bjorn.tysnes@helse-bergen.no.
⁵ Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, Stavanger, Norway; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway; Department of Neurology, Stavanger University Hospital, Stavanger, Norway. Electronic address: guido.alves@sus.no.
⁶ Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, Stavanger, Norway; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. Electronic address: johannes.lange@sus.no.

PMID: 37673381
DOI: 10.1016/j.nbd.2023.106281

Abstract

Given the complexity of Parkinson's disease (PD), achieving acceptable diagnostic and prognostic accuracy will require the support of a panel of diverse biomarkers. We used Proximity extension assays to measure a panel of 92 proteins in CSF of 120 newly diagnosed PD patients and 45 control subjects without neurological disease. From 75 proteins detectable in the CSF of >90% of the subjects, regularized regression analysis identified four proteins (β-NGF, CD38, tau and NCAN) as downregulated in newly diagnosed PD patients (age at diagnosis 67.2 ± 9.4 years) compared to controls (age 65.4 ± 10.9 years). Higher tau (β -0.82 transformed MMSE points/year, 95% CI -1.37 to -0.27, P = 0.005) was also linked to faster cognitive decline over the first ten years after PD diagnosis. These findings provide insights into multiple aspects of PD pathophysiology and may serve as the foundation for identifying new biomarkers and therapeutic targets.

Keywords: Biomarkers; CSF; Parkinson's disease; Proximity extension assay.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Cognitive Dysfunction* / diagnosis
Humans
Middle Aged
Parkinson Disease* / diagnosis
Prognosis
Proteomics